ArticleHealth science reports2026
Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence, Risk Factors at a Tertiary Care Hospital in Nepal: A Cross-Sectional Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Epistaxis is a common complication associated with oral anticoagulant and antiplatelet therapies, often leading to significant morbidity. In recent years, the incidence of cardiovascular disease in Nepal has risen dramatically, driving a widespread use of these medications and heightened concerns regarding bleeding complications. Despite this growing concern, epidemiological data on epistaxis in the Nepalese population is rarely documented. This study aims to determine the prevalence of epistaxis and identify the associated risk factors among patients receiving oral anticoagulants and antiplatelets at a tertiary care hospital in Nepal. Methods: A cross-sectional study was conducted among 284 patients receiving oral anticoagulants at a tertiary care hospital over a 1-year period. Data were collected through structured interviews and medical record reviews. The prevalence of epistaxis with corresponding 95% CI was calculated, and risk factors were analyzed using multivariate logistic regression. A receiver operating characteristic (ROC) curve was determined to establish the suitability of the model. Results: Of the 284 patients, 23.2% (95% CI: 18.4%-28.5%) experienced epistaxis, with 23.2% (95% CI: 18.4%-28.5%) of cases classified as moderate in severity. In multivariate model, age (as continuous) (AOR: 1.068; 95% CI: 1.009-1.13), age (category) ≥ 60 years (AOR: 6.21; 95% CI: 1.20-32.16), male gender (AOR: 1.87; 95% CI: 1.032-3.41), rural residency (AOR: 1.96; 95% CI: 1.04-3.71), having Congestive heart failure (AOR: 2.38; 95% CI: 1.012-5.62), being hypertensive (AOR: 3.14; 95% CI: 1.50-6.53), and individuals on warfarin therapy (AOR: 3.14; 95% CI: 1.50-6.53) emerged as independent predictors associated with the increased risk for experiencing epistaxis. The model revealed a good applicability (AUC: 0.71; 95% CI: 0.64-0.78). Conclusion: Epistaxis remained a common complication among patients receiving oral anticoagulant therapy in Nepal, with advancing age, male gender, rural residency, hypertension, congestive heart failure, and warfarin therapy identified as significant risk factors. These findings underscore the need for enhanced patient monitoring and tailored care plans to mitigate bleeding risks in high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.